Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 22,267 Shares of CVS Health Corp (CVS)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its holdings in CVS Health Corp (NYSE:CVS) by 5.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 352,102 shares of the pharmacy operator’s stock after selling 22,267 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in CVS Health were worth $27,717,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Camarda Financial Advisors LLC acquired a new stake in CVS Health during the 2nd quarter valued at $102,000. Kiley Juergens Wealth Management LLC acquired a new stake in CVS Health during the 2nd quarter valued at $103,000. Legacy Advisors LLC grew its holdings in CVS Health by 7,100.0% during the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock valued at $116,000 after purchasing an additional 1,775 shares in the last quarter. Squar Milner Financial Services LLC acquired a new stake in CVS Health during the 2nd quarter valued at $122,000. Finally, Canton Hathaway LLC acquired a new stake in CVS Health during the 3rd quarter valued at $126,000. 82.42% of the stock is owned by institutional investors.

NYSE CVS opened at $77.90 on Wednesday. CVS Health Corp has a 12 month low of $60.14 and a 12 month high of $83.88. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.87 and a current ratio of 2.34. The firm has a market cap of $74.41 billion, a price-to-earnings ratio of 13.20, a P/E/G ratio of 0.97 and a beta of 0.98.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, beating the Zacks’ consensus estimate of $1.71 by $0.02. CVS Health had a net margin of 1.61% and a return on equity of 18.25%. The firm had revenue of $47.27 billion for the quarter, compared to the consensus estimate of $47.22 billion. During the same period in the prior year, the firm posted $1.50 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year. On average, research analysts expect that CVS Health Corp will post 7.04 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.57%. CVS Health’s dividend payout ratio (DPR) is 33.90%.

In related news, EVP Lisa Bisaccia sold 21,534 shares of the stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $80.00, for a total value of $1,722,720.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Eva C. Boratto sold 13,311 shares of the stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the sale, the executive vice president now directly owns 55,162 shares in the company, valued at approximately $4,256,299.92. The disclosure for this sale can be found here. Insiders have sold a total of 43,409 shares of company stock worth $3,392,097 over the last quarter. 0.53% of the stock is currently owned by insiders.

A number of equities research analysts recently weighed in on the stock. ValuEngine raised shares of CVS Health from a “sell” rating to a “hold” rating in a report on Tuesday. Tigress Financial reaffirmed a “buy” rating on shares of CVS Health in a report on Friday, October 26th. Wolfe Research assumed coverage on shares of CVS Health in a report on Thursday, October 25th. They set a “peer perform” rating for the company. Royal Bank of Canada set a $99.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Tuesday, October 23rd. Finally, Bank of America raised their price target on shares of CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a report on Monday, September 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $86.18.

COPYRIGHT VIOLATION WARNING: “Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 22,267 Shares of CVS Health Corp (CVS)” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.wkrb13.com/2018/11/07/loring-wolcott-coolidge-fiduciary-advisors-llp-ma-sells-22267-shares-of-cvs-health-corp-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Featured Story: How to calculate compound interest

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply